top of page
Colorful Book Spines

PUBLICATIONS

List of recent publications by TC3 members and trainees

2025

2024

2023

2022

2021

2025

  1. Stress disrupts engram ensembles in lateral amygdala to generalize threat memory in mice

  2. Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and Guideline

  3. Effects of different methods of cannabis use on cognition and blood THC: A systematic review

  4. Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [(18)F]FMPEP-d (2) and [(18)F]MAGL-2102

  5. A Systematic Review of Predictors of Vaping Cessation Among Young People

  6. Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review

  7. Brain Function Outcomes of Recent and Lifetime Cannabis Use

  8. Associations Between Cannabis Use and Mental Health in Patients Accessing Treatment for Substance Use Disorders: An Exploratory Cross-Sectional Study

  9. Proximal antecedents and acute outcomes of simultaneous alcohol and cannabis use: Systematic review of daily- and event-level studies

  10. Exploring perceived gender norms about cannabis among treatment-seeking adults in the era of cannabis legalization in Canada: A qualitative analysis

  11. Stereoisomers of cannabidiols and their pharmacological activities - A potentially novel direction for cannabinoids

  12. Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada

  13. Recent Cannabis Use and Accelerometer-Measured Physical Activity and Sedentary Behavior Among Young-to-Midlife Adults: An Analysis of the National Health and Nutrition Examination Survey from 2011 to 2014

  14. Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential

  15. Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan-Canadian, randomized control trial

  16. Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study

  17. Correlates of Using Medically-Authorized Cannabis in a Large Cohort of People Living with HIV Who Use Cannabis

  18. Knowledge of Cannabinoid Content Among People Living with HIV Who Use Cannabis: a Daily Diary Study

  19. Feasibility and Tolerability of Nabilone for the Treatment of Obesity: A Randomized Controlled Pilot Trial

  20. Cannabis Use Trajectories Among People Living With HIV in the Decade Prior to Recreational Legalization in Ontario, Canada (2008-2017)

  21. Acute Cannabis Administration Transiently Reduces Mitochondrial DNA in Young Adults: Findings from a Secondary Analysis of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial

  22. Correlates of cannabis use and cannabis use disorder among adolescents with major depressive disorder and bipolar disorder in the National Comorbidity Survey-Adolescent Supplement (NCS-A)

  23. Using ecological momentary assessment to quantify Δ-9-tetrahydrocannabinol and cannabidiol use across different forms of cannabis: Feasibility in a sample of Canadian young adults reporting frequent cannabis use

  24. Deep Brain Stimulation for Substance Use Disorder: Case Report of Fentanyl Use Disorder and Review of the Literature

  25. Changes in the Sex/Gender Gap in Cannabis Use in Ontario, Canada From 2001 to 2019

  26. Subjective responses to simultaneous alcohol and cannabis use relative to alcohol-only use and cannabis-only use: An ecological momentary assessment investigation

  27. Descriptive norms for simultaneous cannabis and alcohol use predict simultaneous use patterns assessed via daily surveys

  28. Astrogliosis Occurs Selectively in Amygdala of Adolescent Primate and Rodent Following Daily Δ(9)-Tetrahydrocannabinol, Prevented by Cannabidiol Co-Treatment

  29. Designer cannabinoids could be the key to pain relief without adverse effects

  30. The trajectory of substance use disorder among people formerly in foster care: A survival analysis

  31. The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic, randomized controlled trial

  32. Reviewer comment on Yao et al.: "Cannabis Use Prevalence and Correlates in Patients Attending a Canadian Cognitive Clinic"

  33. Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool in Screening Older Adults for Unhealthy Substance Use

  34. Canadian cannabis researcher perspectives on the conduct and sponsorship of scientific research by the for-profit cannabis industry

  35. Evidence of altered monoamine oxidase B, an astroglia marker, in early psychosis and high-risk state

2024

  1. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes

  2. Cannabis and Cannabinoids in the Perioperative Period

  3. Abandon du tabagisme au moyen de la stimulation magnétique transcrânienne répétitive

  4. A systematic review and meta-analysis of neuromodulation therapies for substance use disorders

  5. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease

  6. The State of Synthetic Cannabinoid Medications for the Treatment of Pain

  7. Cannabis use disorder: from neurobiology to treatment

  8. The Cannabis Act: implications for human participant research with cannabis

  9. Neuromodulation for Cannabis Use: A Scoping Review

  10. Cannabis use and mood disorders: a systematic review

  11. Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients

  12. Cannabis use in adolescents and anxiety symptoms and disorders: a systematic review and meta-analysis

  13. Cannabis and Driving in Older Adults

  14. Advice to People with Parkinson's in My Clinic: Cannabis

  15. Cannabis legalization and driving under the influence of cannabis and driving under the influence of alcohol among adult and adolescent drivers in Ontario, Canada (2001-2019)

  16. Cannabinoids dosing for osteoarthritis

  17. Birth, cognitive and behavioral effects of intrauterine cannabis exposure in infants and children: A systematic review and meta-analysis

  18. The Elusive Truth of Cannabinoids for Rheumatic Pain

  19. Clinical and public safety risks associated with cannabis legalization and frequency of cannabis use among forensic mental health patients

  20. Prevention of persistent pain with lidocaine infusions in breast cancer surgery (PLAN): study protocol for a multicenter randomized controlled trial

  21. Environmental Impact of Outdoor Cannabis Production

  22. Positive allosteric modulation of the cannabinoid CB(1) receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics

  23. Expectancies of the Effects of Cannabis Use in Individuals with Social Anxiety Disorder (SAD)

  24. Participant Fraud in Virtual Qualitative Substance Use Research: Recommendations and Considerations for Detection and Prevention Based on a Case Study

  25. Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis

2023

  1. ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids

  2. Circulating Endocannabinoids and N-Acylethanolamines in Individuals with Cannabis Use Disorder-Preliminary Findings

  3. Efficacy of insula deep repetitive transcranial magnetic stimulation combined with varenicline for smoking cessation: A randomized, double-blind, sham controlled trial

  4. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review

  5. Cannabis self-administration in the human laboratory: a scoping review of ad libitum studies

  6. The association of CNR1 genetic variants with resting-state functional connectivity in youth bipolar disorder

  7. Overpoliced and Underrepresented: Perspectives on Cannabis Legalization From Members of Racialized Communities in Canada

  8. The Utility of THC Cutoff Levels in Blood and Saliva for Detection of Impaired Driving

  9. Repetitive transcranial magnetic stimulation for smoking cessation: Next steps for translation and implementation into clinical practice

  10. Motivations for Cannabis Use in Individuals with Social Anxiety Disorder (SAD)

  11. Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review

  12. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome

  13. Advances in targeting neurotransmitter systems in dystonia

  14. Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials

  15. Disentangling Medicinal and Recreational cannabis Use Among People Living with HIV: An Ecological Momentary Assessment Study

  16. Endocannabinoid System Biomarkers in Alzheimer's Disease

  17. Scoping review of guidance on cessation interventions for electronic cigarettes and dual electronic and combustible cigarettes use

  18. The effect of recreational cannabis legalization on rates of traffic injury in Canada

  19. Investigating TSPO levels in occupation-related posttraumatic stress disorder

  20. Daily associations between cannabis use and alcohol use among people who use cannabis for both medicinal and nonmedicinal reasons: Substitution or complementarity?

  21. Changes in self-reported cannabis use during the COVID-19 pandemic: a scoping review

  22. Cannabis companies and the sponsorship of scientific research: A cross-sectional Canadian case study

  23. Cannabis legalization and cannabis use, daily cannabis use and cannabis-related problems among adults in Ontario, Canada (2001-2019)

  24. Risk of Motor Vehicle Collisions and Culpability among Older Drivers Using Cannabis: A Meta-Analysis

  25. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review

  26. Association of cannabis use with neurocognition in adolescents with bipolar disorder

  27. Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review

  28. Youth cannabis use in Canada post-legalization: service providers' perceptions, practices, and recommendations

  29. The Impact of Recreational Cannabis Legalization on Cannabis Use and Associated Outcomes: A Systematic Review

  30. Treating Hyperexcitability in Human Cerebral Organoids Resulting from Oxygen-Glucose Deprivation

  31. On offer to Ontario consumers three years after legalization: A profile of cannabis products, cannabinoid content, plant type, and prices

  32. Impacts of recreational cannabis legalization on use and harms: A narrative review of sex/gender differences

  33. Lessons from 20 years of medical cannabis use in Canada

  34. Murine model for chronic rhinosinusitis: an interventional study

  35. Why a distinct medical stream is necessary to support patients using cannabis for medical purposes

  36. Normative Misperceptions About Cannabis Use in a Sample of Risky Cannabis Users

  37. Co-Use, Simultaneous Use, and Mixing of Cannabis and Tobacco: A Cross-National Comparison of Canada and the US by Cannabis Administration Type

  38. Marked Increase in Amphetamine-Related Emergency Department Visits and Inpatient Admissions in Toronto, Canada, 2014-2021

  39. Does tobacco dependence worsen cannabis withdrawal in people with and without schizophrenia-spectrum disorders?

  40. Δ9-Tetrahydrocannabinol does not upregulate an aversive dopamine receptor mechanism in adolescent brain unlike in adults

  41. Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials

  42. Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study

  43. A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease

  44. Nonopioid Analgesic Prescriptions Filled after Surgery among Older Adults in Ontario, Canada: A Population-based Cohort Study

  45. Cannabinoid Therapy: Attitudes and Experiences of People With Chronic Pain

  46. Characterizing heterogeneity among people who use cannabis for medicinal reasons: A latent class analysis of a nationally representative Canadian sample

  47. The COVID-19 impact and characterization on substance use-related emergency department visits for adolescents and young adults in Canada: Practical implications

  48. Nabilone treatment for severe behavioral problems in adults with intellectual and developmental disabilities: Protocol for a phase I open-label clinical trial

  49. Implementation and Preliminary Evaluation of a 12-Week Cognitive Behavioural and Motivational Enhancement Group Therapy for Cannabis Use Disorder

  50. Pharmacogenetics of Lethal Opioid Overdose: Review of Current Evidence and Preliminary Results from a Pilot Study

  51. The Impact of religiosity/spirituality on slowing the progression of substance use: Based on the National Epidemiological Survey of Alcohol and Related Conditions (NESARC-III)

  52. Patterns of problematic cannabis use in Canada pre- and post-legalisation: Differences by neighbourhood deprivation, individual socioeconomic factors and race/ethnicity

  53. Age, period and cohort effects on time trends in monthly cannabis use in adult population: 1996-2019

  54. An interrupted time series evaluation of the effect of cannabis legalization on intentional self-harm in two Canadian provinces: Ontario and Alberta

  55. Smoking, e-cigarettes and the effect on respiratory symptoms among a population sample of youth: Retrospective cohort study

  56. Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder

  57. Reply to: 'Co-use of opioids with cannabis - evaluating risks and benefits'

  58. Therapeutic cannabis use by patients with cancer in Canada: A national survey of the experiences, opinions and information needs of Radiation Therapists

  59. Perceptions and Prevalence of Cannabis Use in Women With Inflammatory Bowel Disease of Reproductive Age: A Cross-Sectional Study

  60. Effects of sub-chronic nabiximols on biological markers of individuals undergoing a clinical trial for the treatment of cannabis use disorder

2022

  1. Clinical management of cannabis withdrawal

  2. Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature

  3. Monitoring the impact of cannabis use

  4. Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial

  5. Are vaporizers a lower-risk alternative to smoking cannabis?

  6. Neurochemical Alterations in Social Anxiety Disorder (SAD): A Systematic Review of Proton Magnetic Resonance Spectroscopic Studies

  7. The mental health of young people who are not in education, employment, or training: a systematic review and meta-analysis

  8. Effects of combining alcohol and cannabis on driving, breath alcohol level, blood THC, cognition, and subjective effects: A narrative review

  9. Combined effect of alcohol and cannabis on simulated driving

  10. Effects of endocannabinoid system modulation on social behaviour: A systematic review of animal studies

  11. Does cannabis use predict aggressive or violent behavior in psychiatric populations? A systematic review

  12. Influence of personality on acute smoked cannabis effects on simulated driving

  13. Quantifying GABA in Addiction: A Review of Proton Magnetic Resonance Spectroscopy Studies

  14. Mu opioid receptor gene variant modulates subjective response to smoked cannabis

  15. Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease

  16. Association between ABCB1 rs2235048 Polymorphism and THC Pharmacokinetics and Subjective Effects following Smoked Cannabis in Young Adults

  17. Sexually Transmitted Infection Testing After Brief Intervention for Risk Behaviors in School-Based Health Centers

  18. Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review

  19. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis

  20. Neuromodulation to Treat Substance Use Disorders in People With Schizophrenia and Other Psychoses: A Systematic Review

  21. A qualitative study exploring how young people perceive and experience substance use services in British Columbia, Canada

  22. Healthcare practitioner perceptions on barriers impacting cannabis prescribing practices

  23. Cannabis use among pregnant women under different legalization frameworks in the United States

  24. Predictors of pod-type e-cigarette device use among Canadian youth and young adults

  25. Contingency Management for Treatment of Cannabis Use Disorder in Co-Occurring Mental Health Disorders: A Systematic Review

  26. Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia

  27. Healthcare professionals' perspectives on the use of medicinal cannabis to manage chronic pain: A systematic search and narrative review

  28. Associations of cannabis use, opioid use, and their combination with serious psychological distress among Ontario adults

  29. The impact of cannabis legalization for recreational purposes on youth: A narrative review of the Canadian experience

  30. Measurement of public health impacts of cannabis legalization in Canada to reflect policy maker priorities: A rapid scoping review of instruments and content domains

  31. Effects of cannabidiol and Δ9-tetrahydrocannabinol in the elevated plus maze in mice

  32. The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics

  33. 3-Year Follow-up of Lower Risk Cannabis Use Patterns: Evidence from a Longitudinal Survey

  34. The Association of Cannabis Use Disorder with Acute Limb Ischemia and Critical Limb Ischemia

  35. Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review

  36. Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies

  37. Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects

  38. The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19

  39. A machine learning approach to predict e-cigarette use and dependence among Ontario youth

  40. Effects of 28 days of cannabis abstinence on cognition in major depressive disorder: A pilot study

  41. Cannabis Legalization and Detection of Tetrahydrocannabinol in Injured Drivers

  42. Daily Δ(9)-Tetrahydrocannabinol and Withdrawal Increase Dopamine D(1)-D(2) Receptor Heteromer to Mediate Anhedonia- and Anxiogenic-like Behavior Through a Dynorphin and Kappa Opioid Receptor Mechanism

  43. The Association between Recent Cannabis Use and Suicidal Ideation in Adults: A Population-based Analysis of the NHANES from 2005 to 2018

  44. Perspective on Cancer Control: Whither the Tobacco Endgame for Canada?

  45. Co-use of cannabis and prescription opioids in adults in the USA: a population-based, cross-sectional analysis of the NHANES from 2009 to 2018

  46. The effects of acute alcohol administration on circulating endocannabinoid levels in humans

  47. The relationship between cannabis use and legalization frameworks: A cross-sectional analysis using a nationally representative survey

  48. Prospective preference assessment for the Comparison of Analgesic Regimen Effectiveness and Safety in Surgery (CARES) trial

  49. Functional Improvement Trajectories After Surgery (FIT After Surgery) study: protocol for a multicentre prospective cohort study to evaluate significant new disability after major surgery in older adults

  50. Prevalence and factors associated with self-reported exposure to secondhand cannabis smoke in the United States and Canada in 2019

  51. Recent cannabis use and nightly sleep duration in adults: a population analysis of the NHANES from 2005 to 2018

  52. A measure of subjective substance use disorder awareness - Substance Use Awareness and Insight Scale (SAS)

  53. Medical Cannabis and Past-Year Cannabis Use Disorder Among Adult Recreational Users in the United States: Results From a Nationally Representative Sample

  54. Daily cannabis use during the novel coronavirus disease (COVID-19) pandemic in Canada: a repeated cross-sectional study from May 2020 to December 2020

  55. "COVID just kind of opened a can of whoop-ass": The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada

  56. Multiple Substance Use Disorders and Self-Reported Cognitive Function in U.S. Adults: Associations and Sex-Differences in a Nationally Representative Sample

  57. Neurocognitive moderation of repetitive transcranial magnetic stimulation (rTMS) effects on cannabis use in schizophrenia: a preliminary analysis

  58. Measuring Impaired Control over Cannabis Use: Initial Evaluation of the Impaired Control Scale-Cannabis (ICS-C)

  59. In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?

  60. Insula deep rTMS and varenicline for smoking cessation: A randomized control trial study protocol

  61. Correlates of Self-Reported Medicinal Cannabis Use for Physical Health, Mental Health, and Sleep-Related Conditions in a Population-Based Survey of Canadian Youth

  62. Perceived Impact of COVID on Smoking, Vaping, Alcohol and Cannabis Use Among Youth and Youth Adults in Canada

2021

  1. Cannabis use and cannabis use disorder

  2. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials

  3. Review and Consensus on Pharmacogenomic Testing in Psychiatry

  4. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline

  5. Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies

  6. Cannabis, Impaired Driving, and Road Safety: An Overview of Key Questions and Issues

  7. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control

  8. State of the science: cannabis and cannabinoids in palliative medicine-the potential

  9. Combined use of alcohol and cannabis: Introduction to the special issue

  10. Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients

  11. Prevalence and Correlates of Medicinal Cannabis Use Among Adolescents

  12. Perioperative Pain and Addiction Interdisciplinary Network (PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users by a modified Delphi process

  13. The Behavioral Sequelae of Cannabis Use in Healthy People: A Systematic Review

  14. Opioid-sparing effects of cannabinoids: Myth or reality?

  15. Sex differences in the acute pharmacological and subjective effects of smoked cannabis combined with alcohol in young adults

  16. The endocannabinoidome in neuropsychiatry: Opportunities and potential risks

  17. A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness

  18. A novel allosteric modulator of the cannabinoid CB(1) receptor ameliorates hyperdopaminergia endophenotypes in rodent models

  19. Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development

  20. Fatty acid amide hydrolase is lower in young cannabis users

  21. Repetitive Transcranial Magnetic Stimulation for Comorbid Major Depressive Disorder and Alcohol Use Disorder

  22. Co-use and Mixing Tobacco With Cannabis Among Ontario Adults

  23. Online personalized feedback intervention to reduce risky cannabis use. Randomized controlled trial

  24. CB(1) allosteric modulators and their therapeutic potential in CNS disorders

  25. Antiseizure effects of the cannabinoids in the amygdala-kindling model

  26. Preliminary Eye-Tracking Data as a Nonintrusive Marker for Blood Δ-9-Tetrahydrocannabinol Concentration and Drugged Driving

  27. Driving under the influence of cannabis risk perceptions and behaviour: A population-based study in Ontario, Canada

  28. Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review

  29. Influence of Cannabinoid Receptor 1 Genetic Variants on the Subjective Effects of Smoked Cannabis

  30. The influence of conditioned stimuli on [(11)C]-(+)-PHNO PET binding in tobacco smokers after a one week abstinence

  31. Canadian Society of Transplantation White Paper: Ethical and Legal Considerations for Alcohol and Cannabis Use in Solid Organ Listing and Allocation

  32. Cannabis use disorder and perioperative outcomes in vascular surgery

  33. Cannabis use and resting state functional connectivity in adolescent bipolar disorder

  34. Neurostructural Correlates of Cannabis Use in Adolescent Bipolar Disorder

  35. Cannabis clinical research in purgatory: Canadian researchers caught between an inflexible regulatory environment and a conflicted industry

  36. Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings

  37. In reply: Comment on: Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in patients with chronic pain

  38. Computer- vs. nurse practitioner-delivered brief intervention for adolescent marijuana, alcohol, and sex risk behaviors in school-based health centers

  39. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans

  40. Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review

  41. Recent cannabis use and myocardial infarction in young adults: a cross-sectional study

  42. MR Spectroscopy of the Insula: Within- and between-Session Reproducibility of MEGA-PRESS Measurements of GABA+ and Other Metabolites

  43. Correlates of driving after cannabis use in high school students

  44. Substance use in youth at-risk for serious mental illness

  45. Cannabis Use During the COVID-19 Pandemic in Canada: A Repeated Cross-sectional Study

  46. Genetically Predicted Brain C4A Expression Is Associated With TSPO and Hippocampal Morphology

  47. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process

  48. Examining correlates of cannabis users' engagement with a digital intervention for substance use disorder: An observational study of clients in UK services delivering Breaking Free Online

  49. Exploring the Relationship Between ADHD Symptoms and Daily Cannabis Consequences in Emerging Adulthood: The Role of Cannabis Motives

  50. Integrating a brief alcohol intervention with tobacco addiction treatment in primary care: qualitative study of health care practitioner perceptions

  51. Legalization of cannabis use in Canada: Impacts on the cannabis use profiles of youth seeking services for substance use

  52. Survival Probabilities and Predictors of Major Depressive Episode Incidence Among Individuals With Various Types of Substance Use Disorders

  53. The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers

  54. Lower amygdala fatty acid amide hydrolase in violent offenders with antisocial personality disorder: an [(11)C]CURB positron emission tomography study

  55. Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis

  56. Concerns About Recommendations for Perioperative Cannabis Use

  57. Race, cannabis and the Canadian war on drugs: An examination of cannabis arrest data by race in five cities

  58. Effects of daily Δ(9)-Tetrahydrocannabinol (THC) alone or combined with cannabidiol (CBD) on cognition-based behavior and activity in adolescent nonhuman primates

  59. Emerging New Psychiatric Symptoms and the Worsening of Pre-existing Mental Disorders during the COVID-19 Pandemic: A Canadian Multisite Study: Nouveaux symptômes psychiatriques émergents et détérioration des troubles mentaux préexistants durant la pandémie de la COVID-19: une étude canadienne multisite

  60. The missed opportunity for real-world evidence to shape our understanding of medical cannabis

  61. Demographics, Pain Characteristics and Diagnostic Classification Profile of Chronic Non-Cancer Pain Patients Attending a Canadian University-Affiliated Community Pain Clinic

2025
2024
2023
2022
2021

Medical Sciences Building

1 King's College Circle

Toronto, ON, M5S1A8

CANADA

​

​​

​

​

Tel: +1 (416) 978-1160

Email: tc3@utoronto.ca

Web: tc3.utoronto.ca

  • TC3's Bluesky Profile
  • X
  • LinkedIn

Get in touch

bottom of page